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ABSTRACT 
Liver lipid metabolism is coordinated via transcriptional networks composed of transcription 
factors and coregulators. Disturbance of such networks leads to metabolic dysregulation and 
is linked to the progression of obesity-related metabolic disorders, such as non-alcoholic fatty 
liver disease (NAFLD) and cardiovascular disease. Lipid-sensing nuclear receptors, 
particularly liver X receptors (LXRs) and peroxisome proliferator-activated receptors 
(PPARs), play a crucial role in cholesterol and triglyceride regulation and have emerged as 
significant targets for drug development. The major obstacles of targeting nuclear receptors 
are the undesired and often unpredictable side effects due to their genome-wide activities in 
multiple cell-types. Therefore, investigating the associated coregulators and the post-
translational modifications might help to better understand the gene-, cell-type- and signal-
specific regulation of nuclear receptors, especially upon pathophysiological conditions. Of 
particular interest is G-protein pathway suppressor 2 (GPS2), subunit of a fundamental 
corepressor complex, which seems involved in cholesterol homeostasis and anti-
inflammatory crosstalk in a variety of tissues. Although lipid dysregulation and inflammation 
are two major mechanisms to promote metabolic disorders, the role of GPS2 in the 
development of those diseases remained enigmatic. The objective of this thesis was therefore 
to characterize the roles and relationship of GPS2, along with the corepressor complex, to 
individual transcription factors/nuclear receptors at the physiological and genomic level with 
an emphasis on obesity-associated metabolic disorders. 
In Paper I, we discovered a hitherto unknown function of GPS2 in the progression of 
NAFLD to non-alcoholic steatohepatitis (NASH). We demonstrated that GPS2 selectively 
repressed PPARα activity in liver lipid catabolism via the corepressor complex. Hepatocyte-
specific Gps2 knockout mice were protected from diet-induced liver steatosis and fibrosis, 
by enhancing fatty acid oxidation and ketogenesis as result of PPARα de-repression and 
epigenome alterations. Further, by studying human NAFLD/NASH biopsies we found that 
GPS2 expression positively correlated with fibrogenic and inflammatory gene expression. 
Thus, the selective modulation of GPS2-PPARα interactions could be of therapeutic interest 
for NAFLD/NASH. 
In Paper II, we identified GPS2 as a pivotal regulator of lipopolysaccharides (LPS)-induced 
ABCA1 expression and cholesterol efflux, independent of LXR and the corepressor complex, 
in inflammatory macrophages. This study advanced our understanding of GPS2 in linking 
obesity-associated inflammation to cardiovascular diseases. As GPS2 is downregulated 
whilst the circulating endotoxin is elevated in obesity, the LPS-GPS2-ABCA1 axis may 
provide a potential link to explain the increased cardiovascular risk in obesity and T2D. 
In Paper III, we demonstrated that LXRα phosphorylation played a crucial role in NAFLD 
progression in mice. In phosphorylation-deficient LXRα knockin mice, diet-induced NAFLD 
was attenuated by repressing the expression of multiple inflammatory and fibrotic mediators. 
We uncovered a unique group of diet-specific phosphorylation-sensitive LXRα target genes 
in liver, different from those affected by loss of LXRα. Moreover, evidence is provided that 
phosphorylation may modulate the interaction of LXRα with the corepressor complex. This 
study highlights the role of post-translational modifications in defining the gene-selective 
transcriptional activity of nuclear receptors. 
In conclusion, this thesis revealed novel insights into the multifaceted regulatory roles of 
nuclear receptors and GPS2 in altering transcriptional and epigenomic networks linked to 
metabolic and inflammatory processes. These insights may contribute to the better 
understanding of the development of obesity-associated metabolic disorders and to novel 
intervention strategies. 
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1 INTRODUCTION 
1.1 Non-alcoholic fatty liver disease (NAFLD)  
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing globally with 
obesity (1). NAFLD is a chronic liver metabolic disorder which affects up to 30% of the 
world’s adult population currently (2-4). NAFLD is characterized by abnormal liver lipid 
accumulation and ranges from simple hepatic steatosis to severe non-alcoholic steatohepatitis 
(NASH), depending on the extent of steatosis, lobular inflammation and ballooning 
degeneration of the hepatocytes (5, 6). NASH is typically accompanied with peri-cellular 
fibrosis in liver histology, and may potentially progress to more advanced liver diseases, such 
as cirrhosis, liver failure and hepatocellular carcinoma (HCC) (7, 8). The irreversible 
transition to cirrhosis and HCC is the primary cause of mortality associated with NASH (7). 
NAFLD is the second leading cause for liver transplantation in the USA and is predicted to 
become the leading one in the coming years (9). 
 
 
Figure 1 The Spectrum of NAFLD. NAFLD encompasses a spectrum of disease, from left to 
right: healthy liver; steatosis, defined by more than 5% hepatocytes with fat accumulation; NASH, 
which is characterized by steatosis, inflammation, and hepatocyte cell ballooning associated with or 
without liver fibrosis; Cirrhosis, with its characteristic collagen bands surrounding liver nodules. 
Presence of metabolic syndromes, including abnormal obesity, insulin resistance and 
hyperglycemia, atherogenic dyslipidemia, pro-inflammation and systemic hypertension (10), 
has the most explicit biologic link to the progression of NAFLD (8). This association is 
bidirectional, meaning that both metabolic syndrome and NAFLD contribute to the risk for 
each other in a vicious circle (7, 11, 12). Among these metabolic syndromes, T2D is the most 
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potent risk factor for the NASH progression in NAFLD patients (8, 13, 14). More than 70% 
of individuals with T2D have NAFLD (13, 14), among which, the prevalence of NASH as 
well as advanced fibrosis is remarkably enriched compared to nondiabetics with NAFLD 
(15). In addition, metabolic syndrome also promotes the development of adverse 
cardiovascular diseases and increases the overall mortality in NAFLD patients (16, 17). 
Insulin resistance has been characterized as the crucial pathophysiological factor in NAFLD 
for many years (18). All forms of NAFLD are strongly correlated with both hepatic and 
peripheral insulin resistance (19, 20), and NAFLD progression further worsens insulin 
sensitivity (21). However, more and more evidence showed that NASH could occur in the 
absence of insulin resistance (22). This suggested that hepatic steatosis may begin as a simple 
imbalance of liver lipid metabolism, in which the formation of free fatty acids (FFAs) exceed 
their utilization. When excessive FFAs are supplied or their disposal is impaired, their 
metabolites may serve as substrates for the generation of lipotoxic species, and induce 
hepatocellular stress, hepatocyte injury and death, leading to fibrogenesis and genomic 
instability (8). 
The progression rate of NAFLD is highly variable among individuals and has different 
clinical manifestations (8), which reflects the diverse but convergent impact of the 
environment, the microbiome, metabolism, comorbidities and genetic risk factors (23, 24). 
Thus, clarifying the contributions of each factor and sub-classifying the disease based on 
individualized drivers could help to predict the disease progression accurately and apply more 
effective treatments. Multiple other factors such as insulin resistance, lipotoxicity, 
inflammation and genetic susceptibility act in parallel to trigger the disease development (2, 
5, 6, 25).  
Gene expression (transcriptome) analysis during NAFLD progression (26, 27) has identified 
a variety of differentially expressed marker genes, but it is still challenging to demonstrate 
whether the differential expression is also the cause of disease progression in humans.  
Currently, there are no effective therapeutic strategies for NASH patients, which is largely 
due to our limited understanding of the underlying molecular events that control the disease 
initiation and development (5, 6). Thus, major efforts in the field are dedicated to identify 
potential targets to improve liver functions, for example, key factors which promote or 
prevent the progression of NAFLD. 
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1.2 Nuclear receptors in NAFLD 
1.2.1 Imbalanced lipid metabolism 
The liver is the major organ of glucose and lipid metabolism (28) and is composed of multiple 
cell types, mainly hepatocytes and immune cells. Its metabolic functions are tightly regulated 
by hormones and nuclear receptors (NRs).  
Hepatic steatosis is the hallmark feature of NAFLD, which is caused by the imbalances of 
the processes that maintain liver energy homeostasis (29). Conceptually, excess triglyceride 
(TG) storage in liver may result from increased lipid acquisition (uptake of FFAs released by 
adipose tissue from the blood, uptake of TG from chylomicron remnant, and de novo 
lipogenesis (DNL)) and/or decreased lipid disposal (e.g.,fatty acid oxidation (FAO) and 
very-low-density lipoprotein (VLDL) secretion) (Figure 2).  
 
 
Figure 2 Liver lipid homeostasis. Highlighted are the processes involved in maintenance of lipid 
homeostasis. The lipid formation processes are colored red and lipid utilization processes are colored 
blue. 
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1.2.1.1 Lipid acquisition processes 
Dietary TG in the remnant chylomicrons are delivered to the liver (30), and are transported 
into hepatocytes via the low-density lipoprotein (LDL) receptor (LDLR) and LDL receptor–
related protein (LRP) (31-33). 
The FFA released from adipose tissue due to adipose insulin resistance is the key contributor 
to excessive storage of hepatic TG (34). In fasted individuals with obesity and NAFLD, 
circulating FFA and DNL account for ~59% and ~26% of hepatic total TG respectively (35). 
The liver is a major site of DNL, which is tightly governed by insulin and glucose status. 
Insulin and glucose activate two key transcription factors (TFs), sterol regulatory element 
binding protein-1c (SREBP-1c) (36) and carbohydrate response element binding protein 
(ChREBP) (37)), respectively. They both play critical roles in controlling the expression of 
several lipogenic genes, including acetyl-CoA carboxylase (ACC), fatty acid synthase 
(FASN) and stearoyl-CoA desaturase-1 (SCD1) (38, 39). The insulin-induced SREBP-1c 
expression requires the participation of liver X receptor (LXR), a NR that also plays a key 
role in maintaining cellular cholesterol homeostasis (37, 40).  
1.2.1.2 Lipid disposal processes 
Liver also has a major role in distributing lipids to other organs (29). FFAs generated from 
DNL, along with those taken up from circulation, can further be esterified and store in lipid 
droplets as TG or exported from the liver as VLDL particles (41). 
Another important aspect of lipid disposal is via FAO, which is tightly governed by 
peroxisome proliferator-activated receptor alpha (PPARα). Short-chain and medium-chain 
FFA utilization is mainly accomplished via the mitochondrial and the peroxisomal β-
oxidation pathways. The very long-chain FFA (more than 20 carbons) are converted to 
dicarboxylic acid in the microsomal via ω-oxidation pathways before oxidization in the 
mitochondria. During this process, the introduction of a hydroxyl group onto the ω carbon, 
the most distant carbon from the carboxyl group of the FFA, is catalyzed by Cytochrome 
P450 omega hydroxylase, including Cyp4a10, Cyp4a14 and Cyp4a32. The acetyl-CoA, 
derived from β-oxidation, can then be converted to ketone bodies to be used as an energy 
source by other tissues. This process is termed as ketogenesis. The mitochondrial 3-hydroxy-
3-methylglutaryl-CoA synthase (HMGCS2) is the key enzyme (42). 
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In line with this, in the past decades, many glucose- and lipid-sensing TFs/NRs have been 
discovered and validated to be involved in the progression of NAFLD. These key factors 
include, but are not limited to, fatty acid-sensing PPARs (43), oxysterol-sensing LXRs (44), 
bile acid (BA)-sensing farnesoid X receptors (FXRs) (45), and thyroid hormone receptor (TR) 
b (46). 
Further targets are the key enzymes and hormones modulating the liver lipid and glucose 
metabolism, such as SREBP-1c, ChREBP (5), FASN (47), ACC (48), and fibroblast growth 
factors (FGFs) (49, 50), etc. 
1.2.2 Mouse models 
1.2.2.1 High-fat diet (HFD)-induced mouse liver steatosis model 
The association between NAFLD and obesity led to the usage of an HFD. Besides the 
increased body weight, the HFD mice also shows hepatic steatosis, as evidenced by the 
increased haptic TG levels, hepatocyte ballooning and higher fasting serum glucose levels, 
suggesting hyperglycaemia and insulin resistance (51). HFD fed mice better mimic both the 
histopathology and pathogenesis of human NAFLD, as they exhibit the hallmark features 
observed in human NAFLD patients, including obesity and insulin resistance (52). 
1.2.2.2 Methionine- and choline- deficient diet (MCD)- induced mouse liver fibrosis model 
The MCD-induced mouse liver fibrosis model is one of the best characterized models for 
NAFLD studies. The lack of choline and methionine leads to hepatic TG accumulation, liver 
cell death, oxidative stress, distinct inflammation and early development of fibrosis (52). This 
model partially mimics the pathological changes of severe human NAFLD, including severe 
lipid accumulation, macrophage infiltration, liver fibrosis and hepatocyte apoptosis (52). 
1.2.3 Nuclear receptors in lipid metabolism 
1.2.3.1.1 Roles of PPARα in hepatic lipid metabolism  
PPARs consist of three subtypes designated PPARα, PPARβ/δ, and PPARγ. The first 
member PPARα was identified in 1990 and named for its ability to induce peroxisome 
proliferation (53). PPARs ligands include different types of endogenous FFAs and their 
metabolites, and synthetic drugs, including fibrates and thiazolidinedione (54). Activated 
PPARs forms heterodimers with retinoid X receptors (RXRs), and bind to sequence-specific 
target elements, known as the PPAR response element, at the promoter region of various 
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target genes, regulating their transcription. All three PPAR subtypes are highly expressed in 
metabolically active tissues, such as the liver, adipose tissue, skeletal muscle, but they show 
different tissue distribution patterns and ligand specificities, highlighting their tissue 
specificity (55).  
The PPARα functions have been well-characterized in the liver, where it controls fatty acid 
transport, microsomal fatty acid ω-oxidation, mitochondrial and peroxisomal fatty acid β-
oxidation, and ketogenesis in response to feeding and fasting (55). Moreover, PPARα 
activation also ameliorates the detoxification of hydrogen peroxide to protect hepatocytes 
from oxidative stress, which has a crucial role during liver injury in NASH (5). In line with 
this, Pparα knockout (KO) in mice promotes HFD-induced hepatic TG accumulation, 
macrophage infiltration, oxidative stress and hepatocyte apoptosis (Abdelmegeed et al., 
2011). 
In addition, the ability of PPARα to alleviate NAFLD/NASH symptoms at different stages 
has been studied in other mouse models (43). MCD-fed Pparα KO mice developed more 
severe steatohepatitis than wild type (WT) mice (56). Administration of Wy-14643, a PPARα 
agonist, ameliorated MCD-induced liver fibrosis and steatohepatitis in WT mice, but had no 
effect in Pparα KO mice (56). In addition, Bezafibrate (pan-PPAR agonist) and GW501516 
(PPARδ agonist) fed mice were protected from the MCD-induced hepatic TG accumulation, 
liver inflammation and hepatic stellate cells activation (57). On one hand, these agonists 
upregulated a variety of lipid catabolism genes to prevent intrahepatic lipid accumulation (56, 
57). On the other hand, these agonists inhibited liver inflammation and fibrosis, as evidenced 
by the decreased inflammatory cytokines and chemokines expression, decreased fibrogenic 
genes expression and reduced numbers of activated hepatic stellate cells and macrophages 
(56-58). In addition, PPARα could also suppress the acute phase inflammatory response (59, 
60).  
Because PPARα is also highly expressed in adipose tissue, skeletal muscle in addition to liver, 
the hepatic role of PPARα was uncovered until the phenotyping of the recently generated 
liver-specific Pparα KO (LKO) mice. PPARα LKO impaired liver and whole-body fatty acid 
catabolism, resulting in hepatic TG accumulation during fasting, MCD and HFD feeding as 
well as aging. Evidence showed that hepatic PPARα responded to acute and chronic adipose 
tissue lipolysis, and was responsible for circadian FGF21 and fasting-induced FGF21 
expression. Prolonged fasting caused hypoglycaemia and hypothermia in Pparα LKO mice, 
due to defective FAO and gluconeogenesis. Although Ppara LKO mice did not show age-
  7 
related increase in body weight as Pparα KO mice, they developed NAFLD and 
hypercholesterolaemia (61). All these findings underscore hepatocyte PPARα as a potential 
therapeutic target for NAFLD. 
In addition to these preclinical (56, 62-64) studies, the clinical (65) studies further highlighted 
the fundamental impact of PPARα on NAFLD/NASH. In human liver biopsies, the PPARα 
expression negatively correlated with NASH presence and severity (e.g., steatosis, 
ballooning, NASH activity score and fibrosis), visceral adiposity and insulin resistance and 
positively correlated with adiponectin (65). In addition, the histological improvement was 
associated with increased expression of PPARa and its target genes (65). These data indicate 
that PPARα is a critical therapeutic target in NASH. 
1.2.3.2 LXRs in fatty acid and cholesterol metabolism 
As sterol-activated NRs, LXR ligands include oxysterols and certain intermediates in the 
cholesterol biosynthetic pathway (66-69). Once activated by ligands, LXRs heterodimerize 
with RXR to control cholesterol and lipid homeostasis by regulating the expression of 
multiple enzymes, transporters, and modulators involved in these processes (70).  
Of the two subtypes, LXRα is highly expressed in metabolically active tissues and cell types 
such as the liver, adipose tissues and macrophages (66, 67). Thus, LXRα is mainly 
responsible for the activation of DNL genes, such as FASN, SCD1 and SREBP-1c, and 
contributes to liver steatosis (71). Consistently LXRα- and LXRβ-depleted ob/ob mice 
showed reduced hepatic steatosis and improved insulin sensitivity (72). Therefore, the 
lipogenic actions of LXRs could be a major obstacle in the development of LXR agonists as 
drugs for cardiovascular disease (70). 
In addition, LXRs play a central role in cholesterol metabolism, including BA synthesis, 
cholesterol efflux and reverse cholesterol transport (RCT). In both apolipoprotein E (Apoe)- 
and Ldlr- KO mice, the synthetic LXR agonist inhibited the development of aortic lesions 
(73, 74). The cytochrome P450 7A1 (Cyp7a1), a gene encoding the rate-limiting enzyme in 
BA synthesis, was the first direct LXR target gene (67). Several members of the ATP binding 
cassette (ABC) family of membrane transporters, such as ABCA1, ABCG1, ABCG5 and 
ABCG8, are also direct LXR targets, which mobilize cholesterol from the peripheral tissues, 
enhance high-density lipoprotein (HDL) formation, and attenuate atherosclerosis (75-78). 
Moreover, LXRs modulate inflammatory and immune pathways (79) and show anti-
inflammatory and anti-fibrotic activities in experimental models of acute liver disease (80, 
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81). The role of LXRβ in trans-repression of the hepatic acute phase response (APR) will be 
discussed in the next section (82).  
Notably, the expression of both LXRs and their target genes were found to be upregulated 
and positively correlated with intrahepatic inflammation and fibrosis in NAFLD patients (83, 
84). In sum, all these studies suggest that LXRs are important therapeutic targets for liver 
and cardiovascular diseases. More efforts should be dedicated to dissect their beneficial and 
detrimental functions. 
1.3 THE COREPRESSOR COMPLEX 
The major obstacles of NR-targeting drugs are the undesired side effects associated with the 
genome-wide role of TFs in positively and negatively regulating transcription in a highly 
context-dependent manner. Therefore, it is necessary to further dissect and better understand 
the mechanisms of gene-, cell type- and signal-specific TF action to maintain the beneficial 
therapeutic outcomes of TF-targeting drugs while eliminating their side effects.  
TF-interacting coregulators play critical roles in determining the TF activities and the 
associated chromatin states at specific gene loci. Coregulators, commonly categorized into 
corepressors and coactivators based on their positive or negative regulation of gene 
expression, often function highly context-specific (85). Extrahepatic signals trigger the 
exchange of corepressor and coactivator complexes at the TF-containing regulatory 
chromatin elements, mainly promoters and enhancers, to regulate the transcription process. 
This kind of regulation is highly cell-type- or gene-specific, and in some cases the change of 
the sensitivity of cellular responses linked with the progression of human diseases. Most 
coregulators cooperate within histone-modifying enzyme complexes to change local 
chromatin environment, including adding or removing histone methylation and acetylation, 
which is further associated with gene expression or repression. The histone modification 
status, termed as epigenome, can be “read” by chromatin immunoprecipitation coupled with 
next-generation sequencing (ChIP-seq). In addition, ChIP-seq has been applied to identify 
the genome-wide chromatin binding of TFs and coregulators, termed as cistrome (Figure 3). 
However, due to the lack of high-quality antibodies combined with the fact that coregulators 
unlike TFs do not bind chromatin directly, the application of ChIP-seq to coregulators is still 
limited. As a result, how the coregulator/TF switch is coordinated by extracellular signals 
such as hormones and inflammatory cytokines, and how cell- and gene-selectivity of the 
coregulator regulation is conducted through TF-dependent and -independent mechanisms, 
remains currently poorly understood. In terms of liver physiology and disease, such 
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understanding is extremely important since hepatocytes are constantly exposed to chemicals, 
nutrients and hormones (85, 86). 
 
Figure 3 Components of regulatory transcriptional networks in hepatocytes. Highlighted 
are the key components of hepatocyte regulatory transcriptional networks. Both TFs and coregulators 
(including corepressors or coactivators) are responsible to transform multiple extracellular signals into 
physiological pathways and transcriptome changes. To fulfill this, coregulators are recruited to cis-
regulatory chromatin elements, enhancers and promoters, by different classes of TFs. These TFs include 
metabolic NRs (in dark blue), inflammatory TFs (in light blue) and hepatocyte lineage-determining TFs 
(in light orange). Coregulators function within multi-protein histone-modifying enzyme complexes to 
change histone modifications, including (de-)acetylation (Ac) and (de-)methylation (Me), associated 
with the silencing or activation of gene expression. ChIP-seq has been applied to identify hepatocyte 
cistromes, i.e. the genome-wide binding sites of TFs and coregulators, as well as epigenomes, i.e. the 
genome-wide chromatin modifications such as active and repressive histone marks. Ac (acetylation), 
Me (methylation). 
During the past decade, one particular corepressor complex has become the probably most-
studied and best-understood physiological relevant coregulator in the liver. This multiprotein 
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complex contains the core subunits histone deacetylase 3 (HDAC3), nuclear receptor 
corepressor (NCOR, also known as NCOR1), and silencing mediator of retinoic acid and 
thyroid hormone receptor (SMRT, also known as NCOR2). Additional core subunits are G-
protein pathway suppressor 2 (GPS2), transducin β-like protein 1 (TBL1, also known as 
TBL1X) and TBL-related 1 (TBLR1, also known as TBL1XR1) (86-94). A variety of LKO 
mice, and RNAi-mediated knockdown models, have been generated for most of the subunits. 
The major phenotypes are summarized in Table 1.  
 
Figure 4 Liver-specific depletion of individual corepressor complex subunits reveals 
overlapping yet non-redundant roles. In hepatocytes, NCOR, and to a lesser extent SMRT, and 
GPS2 directly interact with TFs, including metabolite-sensing NRs and inflammatory TFs. HDAC3 
requires NCOR interactions for the chromatin recruitment and its repressive function. Highlighted 
are in (A) the assembly and in (B) the structural information of the core subunits of the corepressor 
complex in WT hepatocytes. The coiled-coil domain, TBL1/TBLR1 interaction domain and DAD 
(PDB 1XC5) of NCOR/SMRT are shown in blue. The catalytic domain (PDB 3HGQ) of HDAC3 is 
shown in green. The N-terminal domain (aa1-90, PDB 1UUJ) and WD40 domain (PDB 2H9M) of 
TBL1/TBLR1 are shown in yellow. The coiled-coil domain (PDB 2L5G) and TBL1/TBLR1 
interaction domain of GPS2 are shown in red. In (C) are the alterations that occur upon depletion of 
a specific subunit using conditional KO mice or RNAi knockdown in liver. Models are derived from 
studies that have usually focused on the characterization of one individual subunit, rather than 
characterizing the entire complex. All highlighted examples are discussed and cited in the text. Ac 
(acetylation).  
Figure 4B was adapted from “Oberoi, J., et al. (2011). Structural basis for the assembly of the SMRT/NCoR 
core transcriptional repression machinery. Nature Structural & Molecular Biology 18(2): 177-184. doi: 
10.1038/nsmb.1983” with permission from Springer Nature (License Number: 4570720812746). 
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Table 1 Summary of loss-of-function mouse models revealing liver-specific corepressor 
functions and target TFs. 
 
Protein 
name 
(gene 
name) 
Mouse 
model Key features of the phenotype 
Target 
TF Ref 
GPS2 
(Gps2) Global KO • embryonic lethality around E10  (95) 
NCOR 
(Ncor1) 
Global KO 
• embryonic lethality at E15.5 
• impaired erythroid, thymocyte and CNS 
development 
 (96) 
LKO 
(AAV8-
TBG-Alb-
Cre) 
• developed hepatosteatosis due to increased 
lipogenesis 
RevErb 
LXR 
(97) 
LKO 
(Alb-Cre) 
• repressed lipid synthesis in the fasting state 
• repressed fatty acid oxidation and 
ketogenesis in the feeding state 
• improved liver regeneration after partial 
hepatectomy and blocked 
diethylnitrosamine (DEN)-induced 
hepatocarcinogenesis 
PPARα 
LXR 
ERRα 
(98, 
99) 
LKO  
(Alb-Cre) 
• developed hepatosteatosis due to increased 
lipogenesis 
TR 
 
(100) 
SMRT 
(Ncor2) 
Global KO 
• embryonic lethality before E16.5 due to 
lethal heart defect 
• impaired neural development in forebrain 
• fail to maintenance of the neural stem cell 
state 
RAR (101) 
LKO 
(AAV8-
TBG-Alb-
Cre) 
• no obvious metabolic phenotype - (97) 
LKO  
(Alb-Cre) 
• little effect on most of TR targets in either 
euthyroid or hypothyroid animals 
• de-repressed RAR targets (Cyp26a1) 
RAR (100) 
NCOR/ 
SMRT 
(Ncor1/2) 
NCOR/ 
SMRT LKO  
(Alb-Cre)  
• hepatosteatosis due to activated hepatic 
lipogenesis and lipid storage  
• normal glucose sensitivity 
• increased ChREBP isoforms expression 
TR 
RAR 
(100) 
Global NS-
DADm 
transgenic 
• upregulated lipid-metabolic genes and mile 
hepatosteatosis 
• undetectable HDAC3 enzyme activity, 
abrogated genome-wide HDAC3 
recruitment, as well as increased local 
histone acetylation level  
lipid-
sensing 
NRs 
(102) 
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HDAC3 
(Hdac3) 
Global KO • embryonic lethality before E9.5  (103) 
LKO 
(Mx1-Cre 
plus pIpC 
injection or 
Alb-Cre) 
• hepatomegaly due to hepatocyte 
hypertrophy 
• hepatosteatosis 
• increased serum TG, total serum 
cholesterol, and LDL 
• hypersensitive to insulin 
PPARγ2 (104) 
LKO 
(AAV8-
TBG-Alb-
Cre) 
• alteration in circadian genes 
• hepatosteatosis due to increased 
lipogenesis and sequestration 
• repressed gluconeogenesis 
• improved insulin sensitivity 
RevErb 
HNF4α 
HNF6 
(97, 
102, 
105-
109)  
TBL1 
(Tbl1x) 
TBLR1 
(Tbl1xr1) 
Liver RNAi 
knockdown 
(adenovirus- 
delivered 
shRNA) 
• hepatosteatosis  
• highly elevated VLDL TG 
• inhibited of PPARα activity under both 
normal and HFD conditions 
PPARα 
 (110) 
 
1.3.1  Multiple functions of GPS2 in metabolic and inflammatory regulation 
GPS2 was initially cloned in 1995 as a human cDNA encoding a potential human suppressor 
of conserved G-protein pathways in yeast (111). GPS2 was first identified as a NR-associated 
protein, along with the corepressors receptor-interacting protein 140 (RIP140), NCOR, 
SMRT, in yeast two-hybrid screenings from liver cDNA libraries using PPARa as bait (112, 
113) and later using the orphan receptor small heterodimer partner (SHP) (112). GPS2 was 
independently biochemically purified as an NCOR/SMRT/HDAC3 corepressor complex 
subunit and was suggested to be involved in both NR repression and anti-inflammatory 
crosstalk (88).  
GPS2 is a ubiquitously expressed 37 kDa protein, containing 327 amino acid residues (aa). 
The N-terminal coiled-coil domain (aa 1-90) is sufficient to simultaneously interact with 
NCOR/SMRT as well as with TBL1/TBLR1, thereby forming a three-way corepressor 
complex core structure  (87). Importantly, GPS2 interacts with several liver NRs (e.g., 
PPARa, LXRs, SHP) and inflammatory TFs (e.g., c-Jun) by its C-terminal domain (aa 100-
327) (82, 112, 114, 115), thus serving as a TF-binding subunit of the corepressor complex, 
in addition to NCOR and SMRT.  
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Figure 5 Multiple function of GPS2 in metabolic and inflammatory gene regulation. (A) 
SMRT/GPS2 corepressor sub-complex cooperates with inflammatory TFs, including c-Jun (in 
macrophages and adipocytes), NF-κB and C/EBP (in adipocytes), and repress pro-inflammatory gene 
expression. (B) GPS2 inhibits the activation of HIFa signaling pathway, and maintains the 
mitochondrial activity and adipocyte hyperplasia. (C) The atypical NR SHP inhibits cholesterol 
metabolism by acting as a corepressor for multiple NRs via distinct mechanisms, one involving 
interactions with GPS2. (D) In the presence of activated LXR, GPS2 sequentially recruits KDMs and 
HATs to prime a suitable chromatin environment for the binding of LXR and coactivators, thus 
facilitates the LXR-induced ABCG1 expression. (E) GPS2 mediates trans-repression of the hepatic 
APR by docking to SUMOylated LXR and LRH1. As a consequence, inflammatory signals fail to 
release the corepressor complex from chromatin and inflammatory gene expression remains repressed. 
Ac (acetylation). 
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While metabolic signals that reversibly control GPS2 expression in the liver have not yet been 
identified, post-translational modifications (PTMs) seem to play critical roles in regulating the 
protein function of GPS2. Up to now, methylation (R312, R323) (116-118), ubiquitylation 
(K66) (119) and SUMOylation (K45, K71) (120) of GPS2 have been reported. Further, GPS2 
mutations located in the N-terminal coiled-coiled domain were found in the context of human 
cancers such as medulloblastoma, supporting the role of this domain for appropriate 
corepressor complex function (121). Whether GPS2 mutations play also a role in human 
metabolic diseases such as NAFLD is currently not known.  
1.3.1.1 NR-independent anti-inflammatory GPS2 actions in macrophages and adipocytes 
Both in vivo and in vitro studies indicate that GPS2 has multiple functions in various aspects 
of metabolic and inflammatory regulation (86). Many of these functions are consistent with 
a role of GPS2 as a core subunit of the corepressor complex, while others point to its 
independent roles in transcriptional activation, gene- and cell-type-selective, and even in non-
genomic signaling.  
The key anti-inflammatory role of GPS2 as epigenome modifier was identified by 
macrophage-specific Gps2 KO (MKO) mice along with genomic investigations in tissue 
macrophages and in the mouse macrophage RAW cell line (Figure 5A). The study also 
identifies a GPS2-SMRT sub-complexes as an epigenomic component of metabolic adipose 
tissue macrophage activation in the context of obesity and T2D (90).  
In human adipose tissue, both in adipocytes and infiltrating macrophages, GPS2 expression 
was downregulated in obese subjects, and was inversely correlated to the diabetic status and 
the expression of key inflammatory genes (90, 122). The anti-inflammatory role of GPS2 in 
adipocytes was further confirmed in vivo in aP2-GPS2 transgenic mice (Cardamone et al. 
2012). In addition, a cytoplasmic role of GPS2 was suggested to be required for preventing 
the hyper-stimulation of tumor necrosis factor alpha (TNFα)-induced gene program 
(Interleukin 12 beta (Il-12β) and C-C motif chemokine ligand 2 (Ccl2)) (123).  
Recent studies using adipocyte-specific Gps2 KO mice revealed additional pathways to be 
affected, such as hypoxia-inducible factor 1-alpha (HIF1a) pathways and mitochondrial 
biogenesis, but the underlying genomic vs. non-genomic mechanisms remain to be clarified 
(Figure 5B) (124-126). So far it is probably safe to state that both in macrophages and 
adipocytes GPS2 seems largely, but not exclusively, to cooperate with SMRT to function 
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within an anti-inflammatory corepressor complex targeting inflammatory and other TFs 
(Figure 5A), but surprisingly few NRs (e.g., PPARg-regulated lipolysis in adipocytes).  
1.3.1.2 NR-dependent metabolic and anti-inflammatory GPS2 actions in hepatocytes 
A few studies have begun to analyze the role of GPS2 in mouse and human hepatocytes. 
They revealed that GPS2, via interacting with different NRs (such as LXR, FXR, liver 
receptor homolog-1 (LRH1), HNF4α, and SHP), plays important roles in metabolic and 
inflammatory regulation of liver pathways, some of which are involved in NAFLD/NASH 
(82, 112, 114).  
The two initial studies revealed that GPS2 serves as a physiological coregulator of cholesterol 
homeostasis by affecting cholesterol to BA biosynthesis in the liver (112) and by 
participating in cholesterol transport and efflux in hepatocytes and macrophages via ABCG1 
(114). Activation of FXR initiates a feedback regulatory loop via induction of the orphan 
receptor and corepressor SHP, which suppresses LRH1- and HNF4α-dependent expression 
of CYP7A1 and CYP8B1, the two major enzymes for BA synthesis. The first study suggested 
a model in which GPS2 regulates these genes by two separate mechanisms in opposite ways. 
At the CYP7A1 promoter, GPS2 may serve as a bridging protein to connect the the 
corepressor complex with SHP, thereby triggered repression (Figure 5C). However, at the 
CYP8B1 enhancer and promoter, GPS2 seems required for the recruitment of coactivators, 
thereby triggering activation (112). The second study found that GPS2 is selectively required 
to facilitate LXR-induced ABCG1 expression in human hepatocytes (Figure 5D), while 
having no effect on LXR-induced ABCA1 expression (114). This highlights the fundamental 
molecular differences between transcriptional regulatory elements of two related key LXR 
target genes encoding cholesterol transporters. By dismissing G9a and recruiting histone 
lysine demethylases (KDMs) and histone acetyltransferases (HATs) to trigger H3K9 
demethylation and subsequent H3 acetylation, GPS2 may prime an appropriate local 
chromatin environment to facilitate ligand-induced LXR recruitment and promoter-enhancer 
communication (114). Since GPS2 in that mechanism promotes the chromatin access of a 
target TF, it may exert an unusual ‘pioneer-type’ function, distinct from classic coactivators. 
Indeed, a highly related GPS2 mechanism was identified subsequently also for PPARg in 
adipocytes (Cardamone et al., 2014).  
The anti-inflammatory role of GPS2 can be exemplified by GPS2-dependent actions of LRH1 
and LXRβ in trans-repression of the hepatic APR (82). Importantly, GPS2 was identified as 
a sensor of SUMOylated LRH1 and LXRβ in hepatocytes. This provided the missing link in 
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the trans-repression model, explaining how the NCOR-containing corepressor complex can 
be recruited to NRs in the active/liganded conformation. Specifically, the study demonstrated 
that the GPS2-SUMO-NR complex maintains repression even upon IL-1β and IL-6 
stimulation, thereby inhibiting APR gene expression during inflammation and infection 
(Figure 5E). This study also revealed that in Sumo-1 KO mice the APR was increased, which 
may be caused at least partially by diminished LRH1 SUMOylation (82). In sum, these 
GPS2-focussed studies have conceptually advanced our understanding of multiple functions 
of GPS2 as well as the individual roles of each subunit of the corepressor complex (86). 
1.3.2 NCOR but not SMRT is critical for repression of metabolic pathways in 
hepatocytes 
NCOR (127, 128) and SMRT (129-131) were first identified based on their ability to interact 
with and repress the activity of unliganded NRs. Both NCOR and SMRT are extremely large 
proteins (molecular weight around 270 kDa), which is suitable for forming a scaffold-binding 
surface for simultaneous interactions with target TFs, other coregulators and histone 
modifiers to form a corepressor complex. 
GPS2 and TBL1/TBLR1 bind with each other directly, and simultaneously they both interact 
with distinct conserved regions of the NCOR/SMRT N-terminal repression domains (RD), 
forming a three-component complex (87, 88, 94). HDAC3 directly binds to the deacetylase-
activation domain (DAD) of NCOR/SMRT (88, 132). The DAD binding is critical for 
recruitment and activation of HDAC3 (102, 132, 133). Receptor-interaction domains (RIDs), 
at the C-terminal regions of NCOR and SMRT, have been identified to interact with the 
ligand binding domains of unliganded NRs (128, 134).  
Global genetic deletion of Ncor (96) or Smrt (101) both causes embryonic lethality. Therefore, 
to characterize the in vivo functions, global or liver-specific transgenic mouse models 
carrying different mutations or deletions of NCOR and SMRT have been developed (102, 
135-145). 
Liver depletion of NCOR, not SMRT, causes hepatosteatosis 
The Ncor LKO liver phenocopied Hdac3 LKO metabolic changes, displayed increased 
hepatic lipid accumulation, and the reciprocal reduction of hepatic glycogen content (Figure 
4C). Consistent with the lipid metabolic phenotypes, the transcriptome profiling of Ncor 
LKO and Hdac3 LKO livers also showed high similarity, as the upregulated genes were both 
greatly enriched in lipid and fatty acid metabolism (104, 107). In contrast, unlike the 
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hepatosteatosis phenotype caused by the depletion of liver NCOR or HDAC3, liver SMRT 
depletion showed no obvious changes in the context of lipid metabolism (97). Genome-wide 
chromatin occupancy of NCOR, but not SMRT, revealed a robust circadian rhythm in phase 
with HDAC3, suggesting that NCOR plays a more important role than SMRT in the genomic 
recruitment of HDAC3 in liver (97, 105).  
NCOR represses PPARa-induced fatty acid oxidation and ketogenesis  
In addition, S6 kinase 2 (S6K2), a downstream effector of mammalian target of rapamycin 
(mTORC1) signaling pathway, interacts with NCOR and promotes its nuclear localization, 
which then represses PPARa activity in hepatocytes (146, 147). In line with this, S6K2 has 
markedly elevated activity in ob/ob mice, a genetic mouse model of obesity, and NCOR is 
predominantly localized in hepatocyte nuclei with S6K2. Thus, this reveals a mechanism for 
how energy availability may direct influence the nuclear localization of a key corepressor, 
thereby PPARa repression and hepatic ketogenesis (146).  
Signal-regulated phosphorylation of NCOR 
NCOR repressed lipogenic genes expression as enhanced hepatic lipogenesis and lipid 
storage were observed in Ncor LKO mice (97, 135, 137, 144). In addition, NCOR also 
repressed PPARa-induced hepatic FAO and ketogenesis (146, 147). These apparently 
paradoxical observations indicate that NCOR may select its TF targets in a context-dependent 
manner according to the cellular energy status to orchestrate liver energy metabolism. Indeed, 
the insulin-Akt signaling pathway differentially modulates NCOR activity by inducing 
phosphorylation at serine 1460 during the feeding-fasting transition. Phosphorylated NCOR 
selectively prefers to interact with PPARa and estrogen-related receptor alpha (ERRa) over 
LXRa, and this leads to a de-repression of LXRa target genes to increase lipogenesis whilst 
inhibits PPARa and ERRa target genes to attenuate oxidative metabolism in the liver. 
Therefore, Ncor LKO concurrently induces both lipogenesis and oxidative metabolism due 
to a global de-repression of LXRa, PPARa, and ERRa activity (Figure 6).  
More generalized, PTMs such as phosphorylation could provide an important mechanism by 
which corepressors can switch targets and selectively modulate liver metabolism (98). Indeed, 
multiple phosphorylation sites, some of which are regulated by the insulin-signaling, have 
been identified in NCOR and other corepressor complex subunits in the context of mouse 
liver steatosis and insulin signaling (148). 
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Figure 6 Phosphorylation of the NCOR by the insulin-Akt signaling pathway switches 
its corepressor targets in the liver. NCOR selects its targets depending on the cellular energy 
status. Insulin induces phosphorylation of NCOR serine 1460, which selectively favors NCOR 
interaction with PPARa and ERRa over LXRa. As a result, PPARa/ERRa-dependent oxidative 
metabolism is attenuated due to repression during feeding (A), while LXRa-dependent lipogenesis is 
repressed during fasting (B). Ac (acetylation). 
1.3.3 HDAC3 controls circadian rhythm and physiology 
All the mammalian HDAC superfamily members have a highly conserved deacetylase 
domain. Only HDAC3 is exclusively found in the endogenous NCOR/SMRT corepressor 
complex, suggesting that HDAC3 is the enzyme responsible for histone deacetylation at 
regulatory promoters and enhancers that are controlled by this particular complex. Its 
deacetylase activity requires interactions with NCOR/SMRT (91). Thus, HDAC3 could be 
particularly important for connecting the transcriptional and epigenetic functions of the 
complex in the liver.  
Hdac3 LKO mice revealed the pivotal role of HDAC3 in the regulation of the circadian 
rhythm as well as of hepatic lipid, cholesterol and carbohydrate metabolism (104, 105, 107). 
HDAC3 depletion caused severe liver steatosis, with dramatically elevated hepatic and serum 
TG and cholesterol levels, due to increased DNL and cholesterol synthesis but decreased 
FAO (104, 105) (Figure 4C). However, because the intermediary metabolites were rerouted 
from hepatic gluconeogenesis to DNL and the subsequent sequestration, the Hdac3 LKO 
mice concurrently showed improved glucose tolerance and insulin sensitivity (107).  
Two core components of the circadian clock, the NRs RevErbα and RevErbβ, were found to 
fully account for the circadian rhythmicity of NCOR-HDAC3 occupancy (106, 108) (Figure 
7A and B). Consistently, both the RevErbα- and the NCOR-depleted mice exhibit liver 
steatosis, identical to the Hdac3 LKO phenotype (97, 105). Notably, the Hdac3 LKO mice 
had much more severe liver steatosis than those lacking the two RevErbs (106), suggesting 
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that the NCOR-HDAC3 sub-complex may interact with additional TFs to control the 
expression of genes involved in lipid homeostasis independently of RevErb.  
A recent liver HDAC3 interactome analysis identified the previously known NR corepressor 
and homeodomain TF prospero homeobox protein 1 (PROX1) as an HDAC3-associated 
factor (109). HDAC3 and PROX1 co-occupied extensively at regulatory regions of metabolic 
genes, and liver depletion of PROX1 increased hepatic TG, mimicking Hdac3 LKO 
phenotype. The HDAC3-PROX1 module was recruited to the genome by HNF4α, rather than 
RevErb, because their chromatin recruitment was remarkably reduced upon depletion of 
HNF4α in hepatocytes and REV-DR2 motif was only present in HDAC3-specific peaks (109) 
(Figure 7C). 
 
Figure 7 HDAC3 controls both circadian rhythm and physiology. (A) RevErbα recruits the 
NCOR-HDAC3 complex to its canonical RevDR2 DNA-binding motifs, competing with RORα and 
the associated coactivator complex, to repress circadian clock genes during the light period. (B) 
Simultaneously, HNF6 recruits RevErbα and the associated corepressor complex to mediate circadian 
repression of lipogenic gene expression during the light period. (C) Immuno-precipitation-coupled 
mass spectrometry from mouse liver extracts identified interactions of the HDAC3 complex with the 
homeodomain corepressor PROX1, which mediates the recruitment of HDAC3/NCOR to HNF4α-
bound enhancers to repress lipogenesis. Ac (acetylation). 
Another study revealed an intriguing role of HDAC3 in the age-dependent epigenome 
reprograming linked to metabolic dysfunction (149). In the livers of older mice (21 month), 
loss of HDAC3 chromatin occupancy caused increased histone acetylation and triggered the 
gain of forkhead box protein A2 (FOXA2) at the regulatory elements, which further 
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cooperated with PPARa to upregulate genes involved in lipid synthesis and storage. This 
reciprocal binding of FOXA2 and HDAC3 contributes to the de-repression of PPAR and 
LXR and thereby triggers aging-related liver steatosis (149). 
Although deacetylase enzyme activity of HDAC3 was barely detectable in (NCOR/SMRT) 
DADm mice, the DADm mice failed to phenocopy the dramatic effects of Hdac3 LKO on 
hepatic lipid metabolism (102, 105). This indicates that the HDAC3 enzymatic activity is 
only part of the mechanisms for the key repressive functions of the corepressor complex (97). 
In addition, several deacetylase-dead HDAC3 mutants (Y298A, H134A/H135A, and K25A) 
could largely reverse the liver steatosis in Hdac3 LKO mice (97, 102). Only the HEBI mutant 
of HDAC3, whose interaction with NCOR/SMRT was completely abolished, failed to rescue 
the Hdac3 LKO phenotype. Therefore, the repressive function of HDAC3 in the liver, albeit 
independent of deacetylase activity, totally depends on the interaction with NCOR, while 
SMRT seems dispensable. Thus, HDAC3 functions not independently but only as a subunit 
of the NCOR corepressor complex (97).  
1.3.4 TBL1 and TBLR1 regulate fatty acid oxidation in liver 
Structure data suggest that TBL1 and its homologue TBLR1 directly interact with the 
NCOR/SMRT RID domain and GPS2 via distinct N-terminal regions (87, 94).  
Upon ligand treatment, unlike the dismissal of NCOR-HDAC3, TBL1/TBLR1 could still be 
recruited together with the coactivators. Mechanistically, TBL1/TBLR1 serve as NR 
corepressor-coactivator-exchange factors (N-CoEx), which in the presence of ligands recruit 
the ubiquitin conjugating/19S proteasome complex for the ubiquitination and dismissal of 
the corepressor complex, and facilitate the coactivator recruitment (150, 151).  
To identify the physiological role of TBL1 and TBLR1 in liver, TBL1/TBLR1-depleted 
mouse models were established. Depletion of hepatic TBL1 or TBLR1 resulted in 
significantly increased hepatic TG, serum VLDL TG levels and decreased serum ketone 
bodies levels. Simultaneous depletion of both TBL1 and TBLR1 triggered a much more 
severe phenotype than individual depletion, and these effects were gone in Ppara KO mice. 
Consequently, all the results demonstrated that TBL1 and TBLR1 synergistically prevent 
liver steatosis and hypertriglyceridemia by regulating FAO genes in a PPARa-dependent 
manner (110) (Figure 4C). In line with the N-CoEx function, TBL1/TBLR1 depletion 
triggered the release of known PPARa coactivators and promoted the recruitment of NCOR 
and HDAC3 to the FAO promoters (110). 
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Surprisingly, the TBL1/TBLR1-depleted mice display mildly improved systemic glucose 
tolerance and insulin sensitivity even with severe liver steatosis, similar to the Hdac3 LKO 
phenotype. This suggests that TBL1/TBLR1 may regulate liver lipogenesis as part of the 
corepressor complex (107, 110). 
The coactivator function was independently demonstrated in a previous study which 
demonstrated the requirement of the corepressor core subunits for LXR activation in human 
hepatocytes and macrophages. It was found that depletion of TBLR1 but not of TBL1 
reduced ligand-dependent LXR activation of key target genes (114). Interestingly, TBLR1 
seems to cooperate with GPS2 in this LXR pathway, although at mechanistically distinct 
steps. Therefore, the liver studies confirm that TBL1 and TBLR1, unlike the other core 
subunits of the corepressor complex, function as coactivators for multiple LXR and PPARa 
target genes.  
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2 AIMS OF THIS THESIS 
The objective of this thesis is to understand the roles and relationship of individual TFs/NRs 
and GPS2, along with the corepressor complex, in the development of obesity-related 
metabolic disorders, including NAFLD and cardiovascular diseases. Within three major aims 
the presented studies should advance our knowledge of the regulatory networks and 
mechanisms underlying the development of metabolic disorders: 
AIM 1. To investigate the functions of GPS2 in hepatocytes on lipid metabolism and on 
NAFLD/NASH progression through Gps2 LKO mice and through the analysis of 
gene expression datasets in humans. 
 
AIM 2. To characterize the involvement of GPS2 in LPS-regulated cholesterol efflux 
through Gps2 MKO mice and through in vitro studies using RAW cells. 
 
AIM 3. To explore the role of LXRα phosphorylation in hepatic lipid metabolism during 
NAFLD progression through LXRα-S196A knockin mice. 
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3 METHODOLOGICAL CONSIDERATIONS 
Detailed materials and methods are described in each paper included in this thesis, and this 
chapter aims to highlight specific aspects about some of the methods used.  
3.1 Patients 
The patient clinical information and human liver biopsy transcriptome data are from a 
previously published Belgium cohort (26) collected from overweight individuals visiting the 
Obesity Clinic at the Antwerp University Hospital. The patient information and exclusion 
criteria were all described previously (26). Briefly, the cohort used in this study is composed 
of 104 NASH patients with paired liver biopsies of 35 samples after dietary intervention and 
39 samples after GABY (combined as weight loss group). The fibrosis stage was determined 
by pathological analysis of the liver biopsies. BMI (loss), HbA1c, HDL-c and LDL-c were 
determined as described previously (26), and the study was approved by the Ethical 
Committee of the Antwerp University Hospital (file 6/25/125).  
3.2 Mouse models 
Gps2flox/flox mice were generated at Ozgene Pty, Ltd. (Bentley DC, Australia) using a 
targeting construct, which contained loxP sites flanking exons 2 and 5, followed by a FRT 
site and a neomycin cassette inserted between exons 5 and 6 (90). The targeting vector was 
electroporated into C57BL/6 Bruce4 embryonic stem (ES) cells. The correctly recombined 
ES colony was then injected into C57BL/6 blastocysts. Male chimeras were mated with 
female C57BL/6 mice to get mice with a targeted Gps2 allele. The mice were crossbred with 
C57BL/6 flp-recombinase mice to remove the neomycin cassette to create heterozygous 
Gps2flox/+ mice. The mice were then crossbred with C57BL/6 mice for nine generations 
before being bred with heterozygous Gps2flox/+ mice to get the Gps2flox/flox mice. To generate 
Gps2 LKO mice, Gps2flox/flox mice were crossed with Alb-Cre mice (B6.Cg-Speer6-
ps1Tg(Alb-cre )21Mgn/J; Jackson Laboratory stock no. 003574). Gps2flox/flox mice from the same 
breedings were used as control (labeled as WT). 
Pparα KO mice (152) (B6. 129S4-Pparαtm1Gonz/J; Stock no. 008154) were obtained from 
Jackson Laboratory.  
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Liver-specific Gps2 and Pparα double KO (DKO) mice (Gps2flox/flox Alb-Cre+/-Pparα-/-) 
were generated by breeding the liver Gps2 KO mice with the Pparα KO mice. 
Gps2flox/floxAlb-Cre-/-Pparα-/- mice were used as control.  
Liver-specific Ncor and Smrt KO mice were generated and maintained in Anthony 
Hollenberg’s lab as previously described (100). Generally, Ncorflox/flox and Smrtflox/flox were 
crossed with Alb-Cre mice (B6.Cg-Speer6-ps1Tg(Alb-cre)21Mgn/J; Jackson Laboratory 
stock no. 003574). Ncorflox/flox and Smrtflox/flox mice from the same breedings were used as 
respective control. 
LXRα-S196A mice were generated and maintained in Inés Pineda-Torra’s lab. The 
S196Aflox/flox mouse line was generated by Ozgene Pty Ltd (Bentley WA, Australia). The 
mutant fragment, located on Exon 5, contains a serine-to-alanine mutation at Ser196 
introduced by site-directed mutagenesis. The point mutant exon was delivered into an 
intronic site inside the targeting vector, placed in opposite orientation and thus without coding 
capacity. The targeting construct was electroporated into the Bruce4 C57BL/6 ES cell line. 
Homologous recombinant ES cell clones were identified by Southern hybridization and 
injected into BALB/cJ blastocysts. Male chimeric mice were obtained and crossed to 
C57BL/6J females to establish heterozygous germline offsprings on a pure C57BL/6 
background. The germline mice were crossed to a FLP Recombinase mouse line (153) to 
remove the FRT flanked selectable marker cassette (Flp’d mice). Flp’d mice were then 
crossed with a transgenic C57BL/6 mouse strain carrying a Cre recombinase under the PGK-
1 promoter (154), resulting in the inversion and insertion of the lox-flanked mutated (loxP) 
vector exon 5 region in the sense orientation, and deletion of the WT sequence in most adult 
cell lineages (S196A mice) while WT matching controls carry the WT sequence in the sense 
orientation.  
All animals were randomly assigned to each experimental group. All animal experiments 
were approved by the respective national ethical boards and conducted in accordance with 
the guidelines stated in the International Guiding Principles for Biomedical Research 
Involving Animals, developed by the Council for International Organizations of Medical 
Sciences (CIOMS). Gps2 LKO, Pparα KO and Gps2-Pparα DKO as well as their respective 
control mice strains were bred and maintained at the Center for Comparative Medicine at 
Karolinska Institutet and University Hospital (PKL, Huddinge, Sweden). 
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3.3 Gps2 KO RAW cell line 
The RNA-guided Cas9 nuclease from the microbial clustered regularly interspaced short 
palindromic repeats (CRISPR) adaptive immune system, and have been developed as 
efficient genome editing tool to generate modified cell lines for downstream functional 
studies (155). We applied this technology to delete coding DNA sequences of Gps2 in RAW 
264.7 cells. To minimize the off-target effects, we chose double-nicking strategy using the 
nickase mutated Cas9 with paired single guide RNAs (sgRNAs). The paired sg RNAs were 
designed on CRISPR gRNA design tool Design 2.0. The following sequences of sgRNAs 
(sgRNA1: CACCGGCAAACGGCAGGGTGAGCCT and sgRNA2: 
CACCGGATGTGCCGGTGCAGAGCCC) were inserted into PX461 vector65 (Addgene 
plasmid 48140) and sorted by FACS. The single-cell colonies were validated via sequencing 
for at least five separate T clones, and were further validated by western blot. PX461 empty-
vector transfected and sorted single-cell clones were used as negative controls. 
3.4 Microarray analysis 
Raw-intensity expression files (.CEL files) were imported to R and Bioconductor using the 
Oligo package (156). The same package was used for quantile normalization, background 
correction, and summarization by robust multichip average preprocessing (RMA). The 
normalized log2-transformed expression values were then imported to the Limma (157) 
package for differential-expression analysis by linear modeling. A paired design was used to 
remove the batch effect between the biological replicates. Furthermore, genes with low 
expression (less than the 95th quantile of the negative-control probes) were removed. Genes 
with a P value of <0.05, after adjusting for multiple hypothesis testing using the FDR method, 
were defined as being differentially expressed.  
Correlation matrix was calculated based on expression values in log2 scale of 251 candidate 
NASH genes (26) and GPS2-NCOR-HDAC3 complex components from 104 NASH livers 
at baseline. Genes whose expression significantly correlated with GPS2 expression were 
selected and their correlation with GPS2-NCOR-HDAC3 complex components was plotted 
as heatmap. 
3.5 RNA-seq and data analysis 
RNA was extracted from mice liver biopsies as described above. RNA quality was assessed 
by 2200 TapeStation Instrument (Agilent). PolyA RNA selection was performed using the 
Illumina TruSeq RNA Sample Preparation Kit according to the manufacturer's protocol. 
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RNA-seq libraries were prepared and sequenced on the Illumina HiSeq 2000 platform at 
Bioinformatics and Expression Analysis core facility (BEA, Karolinska Institutet, Sweden). 
Preprocessed reads were aligned to the mm9 transcriptome using the HISAT2 program (158), 
and HOMER (Hypergeometric Optimization of Motif EnRichment, 
http://homer.salk.edu/homer) (159)was used to create the tag directory and count tags in all 
exons. Raw tag counts were imported in to R and Bioconductor and edgeR package was used 
to determine differential gene expression (160). Ggplot2 package was used for the dot plot 
(MA plot and volcano plot) and box plot (161). 
3.6 ChIP-seq sample preparation  
ChIP-seq was performed using both fresh and frozen livers, with protocols modified in each 
condition (90, 162). Briefly, fresh livers were chopped into small pieces and frozen livers 
were pulverized into powder  before subjected to crosslinking. Then the liver pieces were 
crosslinked with 1% formaldehyde (ThermoFisher, 28906) in PBS for 10 min for histone 
modifications, or double crosslinked with 2 mM disuccinimidyl glutarate (DSG) for 30 min, 
followed by 1% formaldehyde for 10 min, for TFs and GPS2. The reaction was stopped with 
glycine at a final concentration of 0.125 M for 5 min. Crosslinked liver pieces were 
disaggregated in ice-cold PBS with protease inhibitor using Dounce Homogenizer first with 
loose and later with tight pestle (Fisher Science, FB56691). Nuclei were isolated using lysis 
buffer 1 (50 mM Hepes-KOH, pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% 
IGEPAL CA-630 and 0.25% Triton X-100), lysis buffer 2 (10 mM Tris-HCl, pH 8.0, 200 
mM NaCl, 1 mM EDTA and 0.5 mM EGTA), and lysis buffer 3 (10 mM Tris-HCl, pH 8.0, 
100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na-deoxycholate, and 0.5% N-
Lauroylsarcosine), and subsequently sonicated for 30 min (30 s ON/ 30s OFF) in the 
Bioruptor Pico (Diagenode). Protein A Dynabeads (Invitrogen) were incubated O/N with the 
antibodies. Each lysate was immunoprecipitated with the following antibodies: anti-
H3K4me3 (Abcam, ab8580, 1 µg), anti-H3K27ac (Abcam, ab4729, 1 µg), anti-PPARα 
(Millipore MAB3890, 5 µg), anti-Polymerase II (Biolegend, 664906, 5 µg), anti-NCOR 
(Bethyl laboratories, A301-145A, 4 µg), anti-SMRT (Bethyl laboratories, A301-147A, 4 µg), 
anti-HDAC3 (Santa Cruz, sc-11417, 5 µg) and anti-GPS2 (4 µg). Formaldehyde crosslinking 
was reversed overnight at 65 °C, and the immunoprecipitated DNA was purified using the 
ChIP DNA Clean & Concentrator Capped Zymo-Spin I (Zymo Research) purification kit.  
For library preparation and sequencing, 2–10 ng of ChIPed DNA was processed using 
Rubicon ThruPLEX DNA-seq kit (TAKARA) or processed at the EMBL Genomics Core 
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Facility (Heidelberg, Germany) using standard protocols, and sequenced in the Illumina 
HiSeq 2000 (50SE reads, EMBL) or NextSeq 550 (75SE reads, Bioinformatics and 
Expression Analysis (BEA, Karolinska Institutet, Sweden) Core Facility).  
3.7 ChIP-seq data analysis 
Raw sequencing files (fastq files), our own sequenced or the published ChIP-seq data from 
European Nucleotide Archive (ENA), were aligned to the NCBI37/mm9 version of the 
mouse reference genome, using Bowtie2 with default settings (163). Duplicated reads were 
removed when using HOMER (159) makeTagDirectory program to generate tag directories. 
Peaks were determined (more than 4-fold enrichment over input and local tag counts and 
FDR less than 0.001) by the HOMER findPeaks program against the input samples.  
Bedgraph files were generated by HOMER makeUCSCfile program. Peak heights were 
normalized to the total number of uniquely mapped reads and displayed in IGV (Integrative 
Genomics Viewer) (164) as the number of tags per 10 million tags. The sequences found in 
GPS2 peaks were subjected to motif analysis to identify potentially over-represented TF-
binding sites using Homer findMotifsGenome program. To generate ChIP-seq heatmap, 
Homer annotatePeaks program was used first to generate the data matrix of read density of 
each ChIP-seq sample in the ±3kb (from the center of the peak) window  with 25 bp bin size. 
The clustering was performed in Cluster 3.0 (165) using self-organizing maps, and then 
visualized in TreeView (166). For statistical analysis of the peaks, raw tag counts were 
imported in to R and Bioconductor. Normalization was performed first based on total 
sequencing tag counts, rather than total tag counts in peaks. The edgeR package was then 
used to calculate fold change as well as p. value based on the normalized tag counts (160, 
167). Ggplot2 package was used for the dot plot (MA plot and volcano plot) and box plot 
(161). 
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4 RESULTS 
4.1 PAPER I: Hepatocyte-specific loss of GPS2 in mice reduces NASH via 
activation of PPARα 
Alterations of regulatory transcription networks and epigenomes in hepatocytes are involved 
in obesity-triggered NAFLD development. The phenotypes of LKO mice depleting 
individual corepressor complex subunits have been linked to multiple target TFs, resulting in 
the modulation of partially opposing liver metabolic pathways. In this study, we combined 
Gps2 LKO mice with human transcriptome datasets analysis and uncovered a hitherto 
unknown role of GPS2 as an epigenetic modulator in hepatocytes that represses PPARα-
dependent lipid catabolism and thereby promotes the progression of NAFLD/NASH in both 
mice and humans.  
4.1.1 Gps2 LKO improves MCD-induced fibrosis in mice 
To explore the function of GPS2 in vivo, we generated Gps2 LKO mice. Intriguingly, Gps2 
LKO presented a dramatical reduction in serum VLDL and total TG level, due to the 
increased lipid oxidation as detected by the increased ketone body production. 
Then we challenged the mice with MCD to induce liver fibrosis. The LKO mice exhibited 
improved liver steatosis and fibrosis, as evidenced by the reduced serum ALT and AST, 
hepatic TG and collagen fiber content, and macrophage infiltration. Consistently, expression 
of fibrotic and inflammatory markers decreased in LKO livers upon MCD, suggesting that 
Gps2 depletion in hepatocytes improves MCD-induced inflammation and fibrosis indirectly 
via enhancing fatty acid metabolism. 
4.1.2 Gps2 LKO improves liver steatosis and insulin resistance  
We further challenged the mice with HFD to explore the role of hepatocyte GPS2 in obesity-
induced liver steatosis and insulin resistance. HFD fed LKO mice gained less body weight, 
showed improved liver steatosis and better glucose control. In addition, serum VLDL and 
total TG levels were reduced in HFD fed LKO mice, due to the reduced lipogenesis gene and 
increased FAO gene expression. Thus, our results suggest that hepatocyte GPS2 plays a key 
role in modulating both lipid metabolism and glucose homeostasis in obese mice. 
 32 
4.1.3 PPARα is a direct target of GPS2 in hepatocytes 
To further investigate the underlying mechanisms involved in the regulatory role of GPS2 in 
the liver, we performed RNA-seq to identify the transcriptome changes and in parallel GPS2 
ChIP-seq for the genome-wide GPS2 occupation, using WT and LKO livers from CD fed 
mice. KEGG pathway analysis revealed the enrichment of PPAR signaling pathways in GPS2 
repressed genes. The up-regulation of PPARα genes (e.g., Pyruvate dehydrogenase 
lipoamide kinase isozyme 4 (Pdk4), Cyp4a14 and Fgf21) in LKO livers were further 
upregulated in fasted and GW7647-treated (a PPARα agonist) mice. To demonstrate the 
requirement of PPARα in the GPS2 mediated repression of lipid metabolic genes, Gps2 and 
Pparα double KO (PGKO) mice were generated. Not surprisingly, the fatty acid oxidative 
effects of GPS2 depletion in the liver disappeared in the absence of PPARα. Collectively, 
these data identify PPARα as a major target for GPS2 in the liver.  
The integrated analysis revealed that the GPS2-dependent transcriptome (RNA-seq) and 
epigenome (H3K4me3 and H3K27ac ChIP-seq) changes were highly correlated genome-
widely as well as at representative gene loci (e.g., Pdk4 and Cyp4a14). Moreover, the 
increased H3K27ac at Pdk4 and Cyp4a14 promoter/enhancer loci upon GPS2 depletion was 
not observed in PGKO versus PKO mice, suggesting that PPARα is required for GPS2-
mediated epigenomic repression at those gene loci. 
4.1.4 GPS2 cooperates with NCOR in hepatocytes 
The apparent PPARα-selectivity of GPS2 repression was surprising as it was unique in 
comparison with LKO models for other corepressor complex subunits. To investigate 
whether GPS2 functions within the corepressor complex or not, we first compared the 
chromatin occupation of NCOR and SMRT with GPS2 in mouse livers, and the transcriptome 
signatures from respective KO livers. Cistrome analysis showed that all three subunits shared 
more than one half of all peaks in the liver genome. However, PPAR signaling pathways 
were only enriched in GPS2 and NCOR, but not GPS2 and SMRT, corepressed genes. In 
addition, GPS2 recruitment was only abolished in observed in Ncor, but not Smrt, LKO livers. 
Based on these results, we concluded that GPS2 cooperates with NCOR in mouse hepatocyte. 
Next, we determined genome-wide chromatin occupancy for GPS2, NCOR, and PPARα, 
along with H3K27ac enhancer mark, in the respective KO livers comparing with WT livers. 
Intriguingly, we found that (i) loss of PPARα caused the release of GPS2 and Ncor from 
chromatin, (ii) loss of NCOR caused the release of GPS2 and the recruitment of PPARα, (iii) 
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loss of GPS2 led to an increased PPARα recruitment, despite not being sufficient for causing 
NCOR release from chromatin. Moreover, the in vitro co-immunoprecipitation results 
showed that full-length GPS2, but not truncated GPS2 variants without the NCOR-
interaction domain or the PPARα-interaction domain, could enhance the NCOR-PPARα 
interaction. These data supported the hypothesis that the presence of GPS2 in hepatocytes 
stabilizes interactions of PPARα with the NCOR complex to repress FAO gene expression. 
4.1.5 Liver GPS2 expression correlates with NASH fibrosis in humans 
We also confirmed clinical relevance of GPS2 in the progression of NAFLD in human 
patients, because we found that GPS2 expression positively correlated with fibrogenic genes, 
including TGFB and TIMP1, in both NAFLD and NASH human subjects. Although there 
was no difference between different NASH stages, GPS2 expression was higher in fibrosis 
NASH than non-fibrosis NASH liver biopsies and was restored after weight loss therapy in 
paired obese human subjects. Therefore, liver GPS2 expression and function might be 
causatively correlated with the progression of NAFLD towards NASH fibrosis via regulating 
PPARα-coupled liver lipid metabolism (Figure 8).  
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expression and PPARα function in 
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Reprinted from “Liang, N., et al. (2019). 
"Hepatocyte-specific loss of GPS2 in mice 
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activation of PPARalpha." Nature 
Communications 10(1): 1684. doi: 
10.1038/s41467-019-09524-z” under the terms 
of the Creative Commons Attribution 4.0 
International License 
(http://creativecommons.org/licenses/by/4.0/) 
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4.2 PAPER II: GPS2 links inflammation and cholesterol efflux by controlling LPS-
induced ABCA1 expression in macrophages  
Macrophages play substantial roles in linking alterations of cholesterol metabolism and 
inflammation to the development of atherosclerosis. Previous studies have identified several 
crosstalk mechanisms that connect cholesterol efflux and inflammation. It has also been 
demonstrated that ABCA1, a main regulator of cholesterol efflux, is specifically necessary 
for the anti-inflammatory effects of LXR ligands. However, the extent to which these 
pathways influence each other has only partly understood.  
To specifically investigate the possible roles of GPS2 in ABCA1 regulation, CRISPR/Cas9-
mediated KO and lentivirus-mediated RNAi knockdown methods were applied to both 
mouse and human macrophage cell lines. Consistent with previous findings (90), GPS2 
deletion significantly up-regulated pro-inflammatory gene expression (e.g., Ccl2 and Ccl7) 
upon LPS treatment. More importantly, we found that GPS2 was specifically required for 
LPS-induced Abca1 expression and cholesterol efflux, independent of LXRα. In addition, we 
identified a functional cooperation between the NF-κB subunit p65 and GPS2 based on ChIP 
assays, as the knockdown of either of them decreased the chromatin recruitment of the other 
at the Abca1 locus. Further, the double knockdown of p65 and GPS2 eliminated LPS-induced 
Abca1 expression. Finally, loss of GPS2 abrogated LXRα trans-repression of pro-
inflammatory gene expression (e.g., Ccl7), although it had minor effects on LXRα-induced 
Abca1 expression. Overall, this work identifies a regulatory chromatin component of 
crosstalk mechanisms between cholesterol efflux and inflammation that affects ABCA1 
specifically (Figure 9).  
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4.3 PAPER III: Impaired LXRα phosphorylation attenuates progression of fatty liver 
disease 
PTMs represent major mechanisms to modify NR activity and function. Despite the well-
recognized importance of LXRα in maintaining hepatic metabolic homeostasis, it is 
unclarified how the PTMs affect LXRα function and influence liver metabolic diseases. To 
directly address the impact of LXRα phosphorylation on NAFLD progression, we generated 
a mouse model harboring an S196A mutation that disrupts LXRα phosphorylation at Ser196. 
Upon high-fat high-cholesterol diet (HFHCD), S196A mice displayed enhanced steatosis, 
but a significantly attenuated progression to steatohepatitis. The gene expression analysis 
showed a unique diet-induced transcriptome that prevents cholesterol accumulation and 
reduces hepatic inflammation and fibrosis. Furthermore, ChIP(-seq)s of LXRα, TBLR1 and 
H3K27ac were performed to understand the mechanism underlying the gene regulation. We 
found that phospho-deficient LXRα altered LXRα and TBLR1 cofactor occupancy and 
promoted H3K27 acetylation at regulatory sites for pro-fibrotic and pro-inflammatory genes. 
Overall, impaired LXRα-Ser196 phosphorylation acts as a novel nutritional molecular sensor 
that profoundly alters the hepatic H3K27ac and transcriptome during NAFLD progression 
(Figure 10). 
 
 
 
Figure 10 Model illustrating that 
phospho-deficient LXRα promotes 
chromatin modifications and 
regulates hepatocyte response to the 
HFHC diet in a gene-specific 
manner. 
Reprinted from “Becares, N., et al. (2019). 
Impaired LXRalpha Phosphorylation 
Attenuates Progression of Fatty Liver Disease. 
Cell Rep 26(4): 984-995 e986. doi: 
10.1016/j.celrep.2018.12.094” under the terms 
of the Creative Commons Attribution 4.0 
International License 
(http://creativecommons.org/licenses/by/4.0/). 
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5 DISCUSSION 
In study I, we discovered that GPS2 triggers the progression of NAFLD/NASH by 
repressing PPARα in mice, and probably in humans. PPARα de-repression in LKO mice 
alleviated liver steatosis upon HFD feeding and improved fibrosis upon MCD feeding, due 
to increased lipid burning as detected by elevated ketone body levels. To be noted, the 
protective phenotype of the Gps2 LKO mice is unique amongst hitherto described coregulator 
LKO mouse models in the context of NAFLD as it is the only model which improved diet-
induced NAFLD instead of worsening it. This study also provides a unique resource of 
hepatocyte ChIP-seq data as we determined chromatin occupancy for GPS2, NCOR, and 
PPARα, along with H3K27ac enhancer mark, in WT and the respective KO livers depleting 
each of these factors. Furthermore, this hepatic function of GPS2 appears to be conserved 
between mice and humans as GPS2 mRNA levels correlated with fibrogenic and 
inflammatory gene expression in human NAFLD/NASH livers. This study might provide 
hepatocyte-based epigenomic explanations for the diverse susceptibility in NAFLD/NASH 
patients to develop more severe stages of liver fibrosis and ultimately liver cancer, in addition 
to alterations in other cell types such as liver-resident immune cells (5).  
In study II, we demonstrated that GPS2 has a unique function in governing endotoxin (LPS)-
induced macrophage cholesterol efflux via ABCA1, through a regulatory mechanism that is 
conserved in mouse and human macrophages. We have reported that the SMRT/GPS2 
corepressor sub-complex crucially controls the macrophage epigenome during activation by 
metabolic stress (90). Complementary to that work, study II improves our understanding of 
GPS2 functions in another aspect, for example, how a corepressor complex subunit GPS2 
regulates macrophages signaling pathways that link obesity-associated inflammation and 
cholesterol efflux to the development of cardiovascular diseases. In particular, our results 
contribute to re-defining the function of GPS2 and ABCA1 in anti-inflammatory trans-
repression mechanisms (82, 114, 168). Although GPS2 protein itself is currently unlikely to 
be a feasible target for drug development, the GPS2-ABCA1-LXR axis may provide a 
potential therapeutic target for further investigation of anti-inflammatory drug candidates. 
In study III, we reported that disrupting phosphorylation at Ser196 (S196A) in LXRα 
retarded NAFLD progression upon HFHCD by repressing the pro-inflammatory and pro-
fibrotic mediators, although it enhanced liver steatosis due to the activation of DNL. Besides, 
the integrated analysis of the transcriptome and H3K27ac uncovered a class of diet-specific 
and phosphorylation-sensitive genes, which are not regulated by synthetic LXRα ligands. 
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Thus, the LXRα-S196A mutation regulates hepatic transcription in a gene-dependent manner, 
rather than conferring an overall gain or loss of LXRα function. In addition, the 
phosphorylation-sensitive Ces1 gene cluster has been reported to be protective from liver 
inflammation and injury (169, 170), although its specific contribution to NAFLD needs to be 
further addressed. Overall, our findings identify LXRα phosphorylation as an anti-
inflammatory and anti-fibrotic therapeutic target, alternatively to synthetic ligands. 
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6 CONCLUDING REMARKS AND PERSPECTIVES 
The three studies included in this thesis focused on the roles of two NRs (PPARα and LXRα) 
and the corepressor complex subunit GPS2 in obesity/T2D-related alterations of lipid and 
cholesterol metabolism. This thesis applied both in vivo and in vitro models to investigate the 
cell-type-specific functions of these NRs and GPS2 in hepatocytes and macrophages 
respectively. By doing so, this thesis revealed novel insights into mechanisms underlying 
NAFLD and atherosclerosis. Therefore, this thesis may contribute to our deeper 
understanding of not only the development, but perhaps also the prevention and future 
therapeutic treatment of these diseases. 
Hepatocytes are the main cell type in the liver responsible for lipid metabolism (28). The 
maintenance of metabolic homeostasis is mainly coordinated at the level of gene expression 
via transcriptional networks composed of TFs, in particular NRs, and associated coregulators, 
including chromatin-modifying complexes. Disturbance of these transcriptional networks 
can lead to dysregulated lipid and glucose metabolism and has been linked to the progression 
of NAFLD (5, 6). 
Utilizing Gps2 LKO mice, we found that depletion of hepatic GPS2 releases the inhibition 
of PPARα targets by the corepressor complex. These PPARα targets include not only the 
local FAO enzymes to aid the hepatic lipid burning, but also endocrine hormone FGF21 to 
regulate glucose and lipid homeostasis and insulin sensitivity in pleiotropic tissues (49, 171, 
172). This provides new evidence for metabolic organ crosstalk, e.g., how signaling pathways 
in the liver could affect the metabolism in other tissues. 
It has been previously reported that a SMRT/GPS2 corepressor sub-complex controls pro-
inflammatory gene activation upon obesity-linked metabolic stress in macrophages (86, 90). 
Intriguingly, mechanistic results of the our Gps2 LKO study suggests that the metabolic 
function of GPS2 in the liver depends on NCOR but not on SMRT. Currently, the reasons 
for this cell type-selective cooperativity are still unclear, but the function of GPS2 within 
different sub-complexes represents a hitherto unrecognized feature.  
Paper I is also amongst the very few corepressor-focused studies that have integrated human 
data and compared mouse and human liver pathways both at the physiological and 
(epi)genomic levels. Despite the high evolutionary conservation of corepressors and their 
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complexes, their genomic targets, i.e. the regulatory promoters and enhancers, can be highly 
divergent between humans and mice. 
Besides the in vivo studies using hepatocyte or macrophage Gps2 KO mice, we also utilized 
GPS2-depleted macrophage cell lines and are currently establishing related hepatocyte cell 
lines. The in vitro studies, on one hand, enabled us to verify and test potential mechanisms 
underlying the phenotypes of the Gps2 KO mice. On the other hand, they also resulted in 
new complementary findings that would have been difficult to detect in vivo. For example, 
we found that GPS2 in macrophages also functions as a p65 co-activator independently of 
the complex, indicating that there is a fraction of ‘free’ GPS2 involved in repression-
independent transcriptional regulation. Whether GPS2 has related function in hepatocytes 
remains to be studied.  
PTMs such as phosphorylation could provide an essential mechanism by which NRs or 
coregulators can switch targets and selectively modulate liver metabolism (98, 148). Using 
LXRα-S196A knockin mice, we showed the physiological consequences of disrupting LXRα 
phosphorylation on NAFLD progression. This may provide an alternative therapeutic target 
for NAFLD aiming the PTMs of LXRα. More generally, we should study much more the 
signal-regulated PTMs that potentially play a major role in the target selection and the 
corepressor/coactivator switch. These issues are highly relevant for the better understanding 
and future targeting of liver disease pathways triggered by aging, nutrition and life style, such 
as obesity-associated NAFLD and hepatic insulin resistance. Finally, regarding therapeutic 
strategies, pathway-specific intervention using rapidly evolving RNA/protein-targeting 
technologies may be possible in near future, but research efforts utilizing humanized liver 
disease models should before scrutinize the pros and cons of targeting hepatic TF-corepressor 
networks. 
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